CD19-directed Cytolytic Antibody [EPC]

858 reported adverse events

Drugs of this class: INEBILIZUMAB

These side effects are most commonly reported by patients taking drugs of the CD19-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 NEUROMYELITIS OPTICA SPECTRUM DISORDER 130
1 OFF LABEL USE 76
2 HEADACHE 50
3 URINARY TRACT INFECTION 44
4 FATIGUE 39
5 NAUSEA 38
6 MYASTHENIA GRAVIS 37
7 PNEUMONIA 36
8 COVID-19 32
9 PAIN 31
See all common reactions for CD19-directed Cytolytic Antibody [EPC]

Drugs of the CD19-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 NEUROMYELITIS OPTICA SPECTRUM DISORDER 130 0.0964
1 BLOOD OSMOLARITY 1 0.0556
2 IMMUNOGLOBULIN G4 RELATED DISEASE 12 0.0376
3 COSTAL CARTILAGE FRACTURE 1 0.0294
4 HEPATITIS E ANTIBODY POSITIVE 1 0.0286
5 POST-DEPLETION B-CELL RECOVERY 3 0.0263
6 CUTIBACTERIUM ACNES INFECTION 1 0.0169
7 BLOOD COPPER DECREASED 1 0.0122
8 B-LYMPHOCYTE COUNT INCREASED 2 0.0108
9 ATYPICAL MYCOBACTERIUM TEST POSITIVE 1 0.0103
See all enriched reactions for CD19-directed Cytolytic Antibody [EPC]